Adaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on Wednesday

Posted by Clark Linder on Nov 9th, 2024

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) will announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $128.23 million during the quarter, compared to the consensus estimate of $58.00 million. Adaptimmune Therapeutics had a negative return on equity of 116.80% and a negative net margin of 51.25%. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptimmune Therapeutics Trading Up 2.6 %

ADAP opened at $0.80 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.09 and a current ratio of 3.09. Adaptimmune Therapeutics has a one year low of $0.42 and a one year high of $2.05. The company has a market cap of $203.80 million, a P/E ratio of -2.28 and a beta of 2.26. The business’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.05.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. StockNews.com upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Adaptimmune Therapeutics in a report on Tuesday, August 13th.

Read Our Latest Analysis on ADAP

About Adaptimmune Therapeutics

(Get Free Report)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.